Who Owns Benadryl?
Benadryl is owned by Johnson & Johnson, a publicly traded American multinational pharmaceutical and consumer goods company. Benadryl operates as Johnson & Johnson's antihistamine allergy relief brand. Johnson & Johnson is headquartered in New Brunswick, New Jersey, USA and trades on NYSE under JNJ.
Parent Company
Johnson & Johnson
Founded
1946
Status
Publicly Traded
Headquarters
New Brunswick, New Jersey, USA
Who Owns Benadryl?
- Parent Company: Johnson & Johnson
- Ownership Type: Brand division
- Company Type: Publicly Traded
- Stock Ticker: NYSE: JNJ
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Benadryl | Johnson & Johnson | Brand division |
History of Benadryl
- Founded: 1946
- Founders: George Rieveschl (original developer)
Benadryl was developed in 1946 by George Rieveschl, a chemist who synthesized diphenhydramine, the active ingredient in the medication. The product was introduced as an antihistamine to treat allergies, itching, and cold symptoms. Benadryl quickly became one of the most widely used antihistamines available to consumers. This scientific breakthrough demonstrated Rieveschl's exceptional ability to develop effective medications that could address common health concerns while creating a new category of over-the-counter allergy relief that would benefit millions of people worldwide.
Johnson & Johnson recognized the commercial potential of Benadryl and began manufacturing and marketing the product. The brand became synonymous with antihistamine allergy relief, establishing a dominant position in the over-the-counter allergy medication market. Benadryl's effectiveness and accessibility made it a household name for allergy sufferers. This rapid commercial success demonstrated Johnson & Johnson's ability to identify and scale innovative healthcare products that could address real consumer needs while leveraging their manufacturing and distribution capabilities to establish market leadership in the allergy medication category.
Throughout the late 20th century, Benadryl expanded its product line to include various formulations for different uses and demographics. The brand introduced products specifically designed for children, adults, and nighttime use. Benadryl became known for its fast-acting relief and wide availability in drugstores and supermarkets. This continuous product expansion demonstrated Benadryl's ability to adapt to changing consumer needs and healthcare trends while maintaining its core effectiveness and safety profile that had made the brand successful for decades.
In recent decades, Benadryl has continued to evolve with new formulations and product variants. The brand has expanded into related allergy and cold symptom categories while maintaining its core focus on antihistamine relief. Benadryl remains a leading antihistamine brand globally, with products available in virtually every country. This ongoing innovation and market leadership demonstrate Benadryl's ability to maintain its competitive advantage through continuous product development while adapting to modern healthcare trends and consumer preferences for more specialized and effective allergy relief solutions.
About Johnson & Johnson
Johnson & Johnson delivered exceptional 2025 results, with CEO Joaquin Duato describing it as a "catapult year" fueled by the strongest portfolio and pipeline in the company's history. Q4 2025 reported sales grew 9.1% to $24.6 billion, with operational growth of 7.1% and adjusted operational growth of 6.1%. Full-year 2025 sales reached $94.2 billion, up 6.0% year-over-year, demonstrating strong momentum across both business segments.
Financial Performance Overview shows Johnson & Johnson's remarkable growth trajectory. The company achieved extraordinary earnings growth with Q4 2025 EPS of $2.10 reported and $2.46 adjusted, while full-year 2025 EPS reached $11.03 reported and $10.79 adjusted. This performance reflects the effectiveness of Johnson & Johnson's strategic focus on innovation and operational excellence across its diverse healthcare portfolio.
Segment Performance demonstrated balanced growth across Johnson & Johnson's two main business segments. The Innovative Medicine segment achieved Q4 2025 sales of $15.8 billion, up 10.0% year-over-year with operational growth of 7.9%. The MedTech segment reached $8.8 billion in Q4 2025 sales, up 7.5% year-over-year with operational growth of 5.8%. For the full year, Innovative Medicine generated $60.4 billion in sales while MedTech contributed $33.8 billion, showing strong performance across pharmaceutical and medical device businesses.
Geographic Performance revealed robust growth across key markets. U.S. sales reached $14.2 billion in Q4 2025, up 7.5% year-over-year with operational growth of 7.5%. International markets achieved $10.4 billion in Q4 2025 sales, up 11.3% year-over-year with operational growth of 6.6%. For the full year, U.S. sales totaled $53.8 billion while international markets contributed $40.4 billion, demonstrating Johnson & Johnson's global reach and market penetration.
2026 Guidance reflects management confidence in continued growth momentum. Johnson & Johnson issued strong guidance for 2026, projecting estimated reported sales of $100.5 billion (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint). This guidance suggests continued strong performance across both Innovative Medicine and MedTech segments, supported by the company's robust pipeline and market-leading products.
Medical Innovation Achievements in 2025 were particularly noteworthy, highlighting Johnson & Johnson's leadership in developing breakthrough treatments. Significant innovations included the approval of CAPLYTA for major depressive disorder, representing a major advancement in mental health treatment. The company also secured approval for RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, demonstrating continued leadership in oncology therapeutics.
Landmark Clinical Data further strengthened Johnson & Johnson's market position. The company reported landmark data for TECVAYLI plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma. This clinical evidence supports Johnson & Johnson's position in treating complex hematological conditions and reinforces the company's reputation for developing innovative cancer therapies.
Strategic Acquisitions enhanced Johnson & Johnson's capabilities and pipeline strength. The acquisition of Halda Therapeutics during 2025 expanded the company's therapeutic capabilities and strengthened its pipeline of future medical breakthroughs across multiple therapeutic areas. This strategic acquisition demonstrates Johnson & Johnson's commitment to investing in innovative technologies and treatments that address unmet medical needs.
Surgical Technology Innovation marked Johnson & Johnson's expansion into advanced medical technology. The submission of the OTTAVA Robotic Surgical System represents the company's entry into the rapidly growing robotic surgery market, positioning Johnson & Johnson to compete with established players in minimally invasive surgical procedures. This innovation reflects the company's strategy of leveraging its medical expertise across multiple healthcare segments.
Operational Excellence contributed significantly to Johnson & Johnson's strong performance. The company achieved operational growth of 5.3% for the full year 2025, with adjusted operational growth of 4.2%, demonstrating effective management of costs and operational efficiency. This operational performance enabled Johnson & Johnson to convert revenue growth into strong earnings improvement and cash generation.
Research and Development Investment continued to drive Johnson & Johnson's innovation pipeline. The company's commitment to R&D investment, spending billions annually on pharmaceutical innovation and medical technology, has created a robust pipeline of future products across multiple therapeutic areas. This investment strategy has positioned Johnson & Johnson for sustained growth and market leadership in healthcare innovation.
Market Leadership Position was reinforced across multiple healthcare segments. Johnson & Johnson maintained dominant positions in oncology, immunology, neuroscience, cardiovascular, surgery, and vision care, with each of these six key therapeutic areas contributing to the company's overall growth and market presence. This diversified leadership reduces dependency on any single therapeutic area and provides multiple growth drivers.
Cash Generation and Financial Strength enabled Johnson & Johnson to pursue strategic initiatives while maintaining shareholder returns. The company generated approximately $19.7 billion in free cash flow for full year 2025, supporting strategic acquisitions, R&D investment, and capital returns to shareholders. This strong cash generation provides financial flexibility for future growth opportunities.
Regulatory Success in 2025 demonstrated Johnson & Johnson's ability to navigate complex regulatory environments and secure approvals for innovative treatments. The company's success in obtaining regulatory approvals for new indications and products reflects the strength of its clinical development programs and regulatory expertise.
Patient Impact remains central to Johnson & Johnson's mission and performance. The company's innovations in 2025, including new treatments for major depressive disorder and various cancers, directly impact patient lives and address critical unmet medical needs. This patient-centric approach drives both commercial success and fulfillment of Johnson & Johnson's broader healthcare mission.
Johnson & Johnson's 2025 performance demonstrates the effectiveness of its strategy focusing on medical innovation, operational excellence, and global market expansion. The combination of strong financial results, breakthrough innovations, and robust pipeline positions the company for continued leadership in the global healthcare industry.
- Founded: 1886
- Headquarters: New Brunswick, New Jersey, USA
- Company Type: Publicly Traded
- Stock: NYSE: JNJ
- Revenue: approximately $88.8 billion (FY2025)
- Employees: Approximately 131,000
Where Is Benadryl Made / Based?
- Headquarters: New Brunswick, New Jersey, USA
- Manufacturing / Operations: United States, Puerto Rico, Europe, Asia
Benadryl Sustainability & Ethics
Benadryl operates under Johnson & Johnson's sustainability framework, implementing environmental initiatives and ethical business practices while maintaining its position as a leading antihistamine brand. The company has committed to achieving net-zero carbon emissions across its operations by 2045.
Environmental Sustainability: Johnson & Johnson has invested in renewable energy for production facilities, with over 20% of its electricity coming from renewable sources as of 2025. Benadryl packaging has been redesigned to incorporate more recycled materials and reduce plastic waste, aligning with Johnson & Johnson's goal to make all packaging recyclable, reusable, or compostable by 2025.
Sustainable Sourcing and Supply Chain: Benadryl ingredients are sourced through Johnson & Johnson's responsible sourcing programs, which require suppliers to meet environmental and ethical standards. The company conducts supplier audits to verify compliance with labor standards and environmental regulations throughout the pharmaceutical supply chain.
Ethical Research and Development: Benadryl benefits from Johnson & Johnson's clinical trial standards, including informed consent processes and independent ethics review boards for pharmaceutical research.
Awards & Recognition
Benadryl has received recognition for its effectiveness in allergy relief treatment and consumer trust, though recent safety concerns have complicated its reputation. The brand ranks among the most recognized over-the-counter allergy medications in consumer surveys.
Consumer Trust and Brand Recognition: Benadryl has been recognized as a trusted allergy relief brand in consumer surveys, reflecting decades of established use for treating allergic reactions, itching, and cold symptoms.
Healthcare Professional Endorsements: Benadryl has received endorsements from allergists, pediatricians, and family physicians for its effectiveness in treating allergic conditions, though many now recommend it selectively given newer alternatives.
Product Quality and Safety Standards: Benadryl adheres to FDA regulations and Good Manufacturing Practices, which regulatory bodies and quality organizations have acknowledged.
Recent safety concerns about diphenhydramine's side effects and potential long-term health impacts have created challenges for Benadryl's reputation, tempering its consideration for consumer safety recognition even as it continues to receive credit for treatment effectiveness.
Benadryl Recalls & Controversies
Benadryl has faced controversies related to safety concerns, particularly regarding diphenhydramine side effects and potential cognitive impacts, leading to increased scrutiny from healthcare professionals and regulatory bodies.
Diphenhydramine Safety Concerns (2025): Major healthcare organizations and medical journals have raised concerns about diphenhydramine's safety profile, particularly its effects on cognitive function and fall risk in older adults. The American Academy of Ophthalmology and World Allergy Organization have published statements suggesting that older antihistamines like Benadryl should be avoided due to risks of grogginess, cognitive impairment, and increased fall risk in elderly patients.
New York Times Investigation (July 2025): The New York Times published an investigation highlighting diphenhydramine's potential harms, including cognitive side effects and increased risk of falls and car accidents, citing medical experts who suggested moving away from older antihistamines like Benadryl.
FDA Safety Warnings (2025): The FDA issued strengthened warnings about serious problems with high doses of diphenhydramine, particularly regarding cardiac effects and central nervous system depression, increasing regulatory scrutiny of Benadryl's safety labeling.
TikTok Benadryl Challenge Controversy: Benadryl faced criticism regarding its association with the dangerous TikTok "Benadryl Challenge" trend, where young people intentionally misused the medication to experience its sedative effects. The American Academy of Allergy, Asthma & Immunology issued warnings about this trend.
Cognitive Impact Research: Scientific evidence published in medical journals suggests that regular diphenhydramine use may contribute to cognitive decline and increased dementia risk in older adults, leading healthcare professionals to recommend newer antihistamine alternatives for this population.
Current Status: As of 2026, Benadryl remains available over the counter in the United States. The FDA has not withdrawn approval or mandated a recall, but updated labeling now more prominently warns against use in elderly patients and against high-dose or off-label use. Johnson & Johnson continues to market Benadryl alongside newer, non-drowsy antihistamine brands in its portfolio.
Brands Owned by Johnson & Johnson
- Acuvue - Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vis...
- Aveeno - American brand of skincare and hair care products specializing in natural ingred...
- Band-Aid - American adhesive bandage brand invented in 1921, owned by Kenvue Inc. Band-Aid ...
- Carefree - American brand of feminine hygiene liners and pads, manufactured and marketed by...
- Clean & Clear - American brand of acne treatment and skincare products specializing in oil-contr...
- Johnson's Baby - American brand of baby care products specializing in gentle formulations for inf...
- Motrin - American brand of ibuprofen pain relief medication owned by Kenvue, the consumer...
- Neosporin - American brand of antibiotic ointment and topical wound care products containing...
- Rembrandt - American brand of whitening toothpaste and oral care products specializing in te...
- RoC - American brand of dermatological skincare products specializing in anti-aging an...
- Stayfree - Feminine hygiene brand of pads and liners owned by Kenvue globally, with North A...
- Tylenol - American brand of pain relief medication and analgesic drugs, flagship product o...
- Zyrtec - American brand of cetirizine antihistamine medication used to treat allergies wi...
Benadryl Ownership: Pros & Cons
Advantages
- +Market-leading antihistamine brand with strong consumer recognition
- +Fast-acting allergy relief for various allergic reactions
- +Wide product range for different uses and demographics
- +Trusted brand reputation built over decades of use
- +Strong distribution network reaching pharmacies and retailers worldwide
- +Backed by Johnson & Johnson's research capabilities and healthcare expertise
- +Affordable pricing with multiple product options
Considerations
- -Drowsiness side effects with some formulations
- -Competition from non-drowsy antihistamine alternatives
- -Not suitable for individuals with certain health conditions
- -Regulatory scrutiny over safety and appropriate use
- -Price pressure from generic antihistamine alternatives
- -Growing medical recommendations against use in elderly patients due to cognitive and fall risks
Frequently Asked Questions About Benadryl
Sources & Further Reading
- Benadryl Official Website
- Johnson & Johnson Sustainability Report
- Johnson & Johnson Healthy Lives Mission
- FDA Diphenhydramine Safety Information
- New York Times: Benadryl Health Risks
- CNN: Common Allergy Medication Risks
- World Allergy Organization Journal: Diphenhydramine Analysis
- American Academy of Ophthalmology: Antihistamine Safety
- AAOA: Dangerous Benadryl Trend Warning
- Dartmouth Health: Benadryl Effectiveness Analysis
- MedlinePlus: Diphenhydramine Drug Information
- PMC: Diphenhydramine Safety Research
- Johnson & Johnson Investor Relations
- SEC EDGAR: Johnson & Johnson (JNJ) filings
- NYSE: Johnson & Johnson (JNJ)
- Wikidata: Benadryl entity
Where to Buy
Disclosure: We may earn commission from purchases
Benadryl on AmazonCompetitors to Benadryl
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Kenvue | USA | 1987 | Mass market | Global | All-ages | |
| Haleon | United Kingdom | 1966 | Mass market | Global | All-ages | |
| Kenvue | USA | 1974 | Mass market | Global | All-ages | |
| Kenvue | USA | 1955 | Mass market | Global | All-ages |
Learn More About Competitors
Zyrtec
Owned by Kenvue
American brand of cetirizine antihistamine medication used to treat allergies without drowsiness, owned by Kenvue Inc., the consumer health company spun off from Johnson and Johnson in 2023.
Otrivin
Owned by Haleon plc
Over-the-counter nasal decongestant spray for relieving nasal congestion from colds and allergies, owned by Haleon plc.
Motrin
Owned by Kenvue
American brand of ibuprofen pain relief medication owned by Kenvue, the consumer health spinoff from Johnson & Johnson, which is being acquired by Kimberly-Clark in a $40 billion deal announced in November 2025.
Tylenol
Owned by Kenvue
American brand of pain relief medication and analgesic drugs, flagship product of Kenvue Inc., the consumer health company spun off from Johnson and Johnson in 2023.
Competitive Analysis
Market Positioning: Benadryl competes with 4 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Johnson & Johnson Stock Information
Jobs at Johnson & Johnson
Latest News About Benadryl
Related Articles About Benadryl
View more articles
Your Entire Medicine Cabinet Might Be J&J
Tylenol, Band-Aid, Listerine, Neutrogena, Aveeno, Benadryl. Johnson & Johnson's consumer health portfolio is extensive. Here is a complete look at the brands now under Kenvue.
Who Owns the Sunscreen Market
Beiersdorf owns Nivea Sun and Coppertone. L'Oreal owns La Roche-Posay and Anthelios. Edgewell owns Banana Boat and Hawaiian Tropic. Here is who controls the global sunscreen market in 2026.
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Acuvue
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.